FERRETAB® COMP.

ABOUT BRAND

  • Brand name:

    FERRETAB® COMP.

  • Dosage form:

    Capsules

  • Composition:

    1 capsule contains: 3 ferrous fumarate minipills and 1 folic acid minipill.
    Active pharmaceutical substance: ferrous fumarate – 163,56 mg (solid equivalent to 152,1 mg, equivalent to 50 mg of ferrum), folic acid – 0,54 mg (solid equivalent to 0,5 mg).
    Excipients: ferrous fumarate minipills: lactose monohydrate – 3,42 mg, colloidal silicon dioxide – 0,6 mg, magnesium – 0,6 mg, methyl methacrylate and ethyl acrylate copolymer [2 : 1] – 4,66 mg, folic acid minipill: lactose monohydrate – 24,21 mg, microcrystalline cellulose – 24,25 mg, colloidal silicon dioxide – 0,5 mg, magnesium – 0,5 mg.
    Capsule body: gelatin – 36,4804 mg, azorubine dye – 0,0742 mg, quinoline yellow dye – 0,1484 mg, titanium dioxide – 0,4960 mg.
    Capsule cap: gelatin – 24,3203 mg, azorubine dye – 0,0498 mg, quinoline yellow dye – 0,0996 mg, titanium dioxide – 0,3303 mg.

  • ФЕРРЕТАБ® КОМП.
  • ФЕРРЕТАБ® КОМП.

Combined medicines of iron organic salt and folic acid in capsules of prolonged action for the iron deficiency treatment and prevention, especially during pregnancy.

 

Description

Size 2 solid gelatin capsules, red body and cap. Capsule contains 3 reddish-brown round flat minipills (ferrous fumarate) and 1 yellow round flat minipill (folic acid). Inclusions are allowed on tablets.

 

Indications

Treatment of latent iron deficiency and iron deficiency anemia, combined with folic acid deficiency, including during pregnancy.

 

Counterindications

— Hypersensitivity to the active ingredients or to any of the excipients

— Diseases accompanied by accumulation of iron in the body: hemochromatosis, hemosiderosis, chronic hemolysis

— Iron absorption disorders: sideroachrestic anemia, thalassemia, lead anemia

— Hemoglobinopathies, hemolytic anemia, aplastic anemia, pernicious anemia, anemia not caused by iron and folic acid deficiency

— Gastrointestinal disorders

— Patients with rare hereditary problems of galactose intolerance, lactase deficiency or malabsorption

— Children and adolescents under 18 years of age

Events 25 February
    en_USEnglish